Oncolytic vaccinia virus as a precision cancer vaccine platform

Shae J Komant,Jun Li Wang,Nicole Favis,Cyril Alex,David H Evans,Ryan S Noyce,Troy A Baldwin

DOI: https://doi.org/10.1101/2024.08.16.608170

2024-08-19

Abstract:Oncolytic viruses (OVs) are a unique immunotherapeutic tool as they possess the ability to selectively replicate in and kill tumor cells while also having the potential to induce potent anti-tumor immune responses. Further, the use of OVs as payload delivery systems to the tumor offers a precision approach to enhancing immune responses generated during OV therapy through the viral expression of immune stimulating molecules in the tumor. Notably, Vaccinia virus (VACV) is a strong oncolytic candidate due to its ability to infect a wide range of cancer cells, and a genome capable of harbouring large inserts of exogenous DNA. Peptide-Major Histocompatibility Complexes (pMHC-I) are vital components of the immune recognition of tumors, leading to the activation of antigen specific T cells and targeted killing of cells. Here, we examined the use of an oncolytic VACV (VACVΔ4x) expressing a single chain trimer (SCT) pMHC-I complex (VACVΔ4x-SCT) encoding a tumor associated or specific antigen. VACVΔ4x-SCT treatment was investigated in two immunologically cold tumor models, B16F10 melanoma and EMT6 breast cancer. VACV expression of tumor specific SCTs lead to drastic differences in tumor growth between the two models, where enhanced tumor clearance was observed in the EMT6 model. Tumor antigen specific CD8+ T cells were isolated from both tumor and spleen following VACV-SCT treatment, indicating the ability to induce targeted tumor specific responses with viral therapy. Initial tumor clearance was also observed to be protective in the EMT6 model, leading to tumor rejection upon subsequent challenge. Overall, we demonstrate the ability to generate a personalized cancer vaccine capable of inducing system recognition and elimination of tumor cells, validating VACV as a potential vaccine platform.

Immunology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to develop a cancer vaccine platform capable of precisely inducing anti - tumor immune responses. Specifically, researchers enhance the specific immune recognition and killing ability of tumor cells by constructing an oncolytic vaccinia virus (VACV) that expresses single - chain trimer (SCT) peptide - major histocompatibility complex class I (pMHC - I) complex. This strategy aims to overcome the challenges encountered in the clinical application of traditional oncolytic virus therapies, such as insufficient immune response or tumor escape mechanisms.

The key points mentioned in the paper include:
- **Oncolytic viruses as immunotherapeutic tools**: Oncolytic viruses can selectively replicate in tumor cells and kill these cells, while also inducing strong anti - tumor immune responses.
- **Characteristics of VACV**: Vaccinia virus has become an ideal oncolytic virus candidate because of its wide host range, the ability to carry a large amount of exogenous DNA, and the ease of laboratory manipulation.
- **Importance of pMHC - I complex**: The pMHC - I complex plays a key role in tumor immune recognition, which can activate antigen - specific T cells, leading to the targeted killing of tumor cells.
- **Experimental models and results**: Researchers used two immunologically cold tumor models - B16F10 melanoma and EMT6 breast cancer models - to test the effect of VACV Δ4x - SCT virus expressing specific tumor antigen SCT. The results showed that in the EMT6 model, VACV Δ4x - SCT treatment significantly enhanced tumor clearance and induced a specific CD8+ T - cell response, demonstrating the effectiveness of this method.

In summary, the core objective of this paper is to engineer oncolytic viruses to express tumor - specific antigens, thereby enhancing the immune system's ability to recognize and attack tumors, and ultimately achieving the development of personalized cancer vaccines.